| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1fd34fea6801ea1d9286475b96be2d26 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
1996-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0bc43a3268592016a48ce3c7162ac29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9dd1ef156ca4fb875efc430d3eb1f522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1e94a677f9816b66ea00eb1ad93f438 |
| publicationDate |
1997-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0773293-A2 |
| titleOfInvention |
Genetically engineered tumour cell lines and their use in the screening of antitumour-compositions |
| abstract |
The invention describes a novel method for determining the mass of vital tumor cells from xenografts in animal models. Genetically modified cells that form a tumor after transplantation synthesize a secreted reporter protein. This is shown by way of example for a secreted form of human placenta-specific alkaline phosphatase (SEAP). This can be detected in the serum of experimental animals or in culture supernatants using an enzyme test. The activity of SEAP in the serum correlates with the number of vital tumor cells in the animal and can be measured before the formation of a palpable tumor. The use of such genetically modified cell lines in subcutaneous and orthotopic tumor models is shown in the invention. Dicistronic eukaryotic expression vectors are used for the stable transfection of the mammalian cell lines or tumor cells used. Under the control of a constitutive or inducible promoter element, these vectors contain the gene coding for SEAP, coupled to a second gene. This codes, for example, for a receptor tyrosine kinase which transforms in the event of overexpression, such as erbB2 / HER2. |
| priorityDate |
1995-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |